Heart Failure

Regulatory Matters Related to Monitoring Devices

Regulatory Issues Related to the Introduction of New Percutaneous Pumps

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

New Endpoints and Experimental Designs for Devices for Chronic Heart Failure (Breakthrough)

Measuring Health Equity in Clinical Settings: Tips for Healthcare Leaders

Reach, Access, and Affordability: Implementing Therapies for All

Designing Clinical Trials to Facilitate Better Implementation: Tips for Researchers

Leveraging Remote Patient Monitoring to Implement GDMT

Amyloidosis Is Everywhere: Is It Really a Rare Disease?

How Can We Find Cardiac Amyloidosis Not Amyloid Early?

The Importance of Optimizing Medical Therapy in Patients Undergoing Coronary and Structural Interventional Procedures

AI in Cardiac Imaging: What is Hidden in the CT and Radiograph?

It's All in Front of Our Eyes: How to Exploit EMR in the Heart Failure Management

AI: What Does All of This Mean for Heart Failure Patients and Doctors

A Multidisciplinary Approach to a Patient With Cardiac Mass: LV Biopsy With Transeptal Approach to Diagnose Melanoma.

Avoiding Treatment In Hospital With Furoscix To Manage Congestion At Home: A Pilot Study

Does Obesity Paradox Exist in Cardiogenic Shock?

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre Cardiogenic Shock

Ventricular Load: Five Decades of Fundamental Cardiovascular Physiology and Biology

Ventricular Unloading and Reverse Remodeling in Heart Failure

Unloading as a Bridge to Native Heart Recovery in Advanced Heart Failure

Unloading as a Bridge to Native Heart Recovery in Advanced Heart Failure: A Glimpse Into the Future

EKG in the Screening, Diagnosis and Management of Heart Failure

AI in Cardiac Imaging: What is Hidden Behind the ECHOCARDIOGRAPHIC Image?

Physiological Modeling at Rest and Exercise of a Novel Right-to-Right Cardiac Shunt

The Lymphatic System and The Role in Heart Failure

Novel Imaging Methods and Interventions of the Lymphatic System

Lessons Learned from Fontan Patients Relevant to Heart Failure

Harnessing the Lymphatic System the Treat Heart Failure

Clinical Feasibility of a Novel Right-to-Right Cardiac Shunt in Pulmonary Hypertension using Off-the-Shelf Devices

Assessing RV Function and RV-PA Coupling in the Contemporary Era: The Gold Standard Approach - PV Loops

Assessing RV Function and RV-PA Coupling in the Contemporary Era: Clinical Assessment (Let's Be Practical)

Assessing RV Function and RV-PA Coupling in the Contemporary Era: Novel Applications of Invasive RV PV Loops

Assessing RV Function and RV-PA Coupling in the Contemporary Era: Noninvasive RV PV Loops

How to Determine When the RV Becomes the Problem in PAH

Why Invasive Cardiopulmonary Exercise Testing; What is the Added Value?

Technical Aspects of Doing Supine Exercise Testing in the Cath Lab

Technical Aspect of Doing Upright Exercise Testing

How to Optimize “Usable” Hemodynamic Tracings During Exercise: Tips/Tricks, Do's and Don'ts

Can High Quality Hemodynamic Exercise Test Be Performed by a Majority of Heart Failure and Interventional Cardiologists?

What Limits Exercise Tolerance in Heart Failure: The Big Picture

Lessons Learned from Exercise Studies of LVAD Patients

HFpEF: Beyond Pulmonary Capillary Wedge Pressure

Deep Dive: The Role of the Heart in Limiting Exercise Tolerance

Diagnosis and Classification of Pulmonary Hypertension in 2023

Monitoring Devices in Pulmonary Hypertension - Moving Beyond CHAMPION

Shunt Devices in Pulmonary Hypertension Management

Pulmonary Artery Denervation: Innovative Pulmonary Hypertension Therapies

BPA in CTEPH Management

PYP Scintigraphy is Insufficient as a Non-Invasive Diagnostic Tool: Time for PET!

Dichotomizing ATTR-CA Into Neurologic and Cardiac Phenotypes Is So 2010..What Works For One Works For the Other

Will Gene Therapy With CRISPR Cure ATTR-CA?

NeuroCardiology: Tapping the Nervous System to Understand and Treat Heart Failure

Exercise Capacity and Health-Related Quality of Life With Furoscix:  Data From the AT HOME Pilot Study

Are We Ready to Start Systematic Screening for ATTR-CA? AS Early Diagnosis is Key

Heart Failure Journal Editors' Forum: JACC: Basic to Translational Science

Heart Failure Journal Editors' Forum - Circ: Heart Failure

Heart Failure Journal Editors' Forum: JACC - Heart Failure

Heart Failure Journal Editors' Forum - JACC: Clinical Electrophysiology

Heart Failure Journal Editors' Forum: Structural Heart

Influence of Serum Potassium on the Decongestive Potential of Spironolactone: Insights from the ATHENA-HF Trial

Biological vs Physical Reverse Remodeling in Heart Failure: Implications for Device-Based Therapies for HFrEF

Heart Failure Journal Editors' Forum: Journal of Heart and Lung Transplant

Heart Failure Journal Editors' Forum: JCF

The Projected Burden of Heart Failure

A Payors Perspective: Innovative Models to Reduce Cost

Who Bears the Cost of Innovation?

Medicare Coverage and Postmarket Evidence on Emerging Cardiovascular Devices

Are All Incentives Altruistic?: The Importance of Measurement

Now is Not Soon Enough: Why Improving Patient Diversity in HF Trials is a Key Priority

FDA Guidance on Meaningful Representation in Clinical Trials

Training Investigators to Advance Diversity and Inclusion

Recruitment Strategies for Vulnerable and Marginalized Trial Participants

The Leaders of the Pack: Why Improving Investigator Diversity in Heart Failure Trials is a Key Priority

Guideline Directed Medication Therapies (GDMT): Decreasing Time From Initiation to Core Therapy Use

GDMT: Overcoming Polypharmacy

The Role of Nurses, APPs, and Pharmacists to Optimize Population Heath Heart Failure Outcomes: The Hospital Heart Failure System Perspective

Optimizing Euvolemia as Part of GDMT

Guideline Directed Medication Therapies (GDMT): Decreasing Time From Initiation to Core Therapy Use - Case Presentation

Advanced Heart Failure in ACHD - How Do We Define It?

What's the Status of Advanced Heart Failure Care in ACHD Now? MCS, Listing Status and Outcomes

How Do We Improve Advanced Heart Failure Outcomes in ACHD? ACTION Learning Network

Applications of Gene Therapy in Cardiomyopathies

The Multiverse of HFpEF: All Roads Lead to Functional Limitation

New Insights Into the Pathophysiology of HFpEF

Medical Therapies Work for HFpEF: What, When, How

Interventional Therapies for HFpEF

Does this patient have HFpEF and if so how to treat? - Mystery Case 1

Does this patient have HFpEF and if so how to treat? - Mystery Case 2

Medical Therapies of Decompensated Heart Failure and the Concept of "Diuretic Resistance"

Debate: Revascularization in Chronic Heart Failure after REVIVED - is GDMT enough?!

Debate: Revascularization in Chronic Heart Failure after REVIVED - Revascularize!

Revascularization or Medical Therapy in Chronic Heart Failure - Case Resolution

Case Presentation: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD

Case Presentation: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD - Mitraclip!

Case Presentation: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD - Tx/VAD

Case Resolution: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD

Medical Therapies for Heart Failure: The Foundation of Foundational Therapies for Heart Failure

Medical Therapies for Heart Failure: Beyond the Four Foundational Therapies: Vericiguat and Omecamtiv Mecarbil

The Role of Monitoring Devices in Optimizing Medical Heart Failure Therapies

Emerging Medical Pathways for Heart Failure Therapies

Opening Talk: Innovation and Technologies to Enhance the Care of Patients With Heart Failure

The Impact of SGLT2 Inhibitors Across the Spectrum of Heart Failure

SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

Contemporary Implementation of Guideline-Directed Therapy for Heart Failure

Recent Advances in the Medical Treatment of Patients With Decompensated Heart Failure

The AI Revolution and How It Is Impacting Health Care Delivery in Heart Failure

Assessing the Residual Risk: What Gaps Should New Technologies Fill?

Latest Data From REVIVED

Revascularization or Medical Therapy in Chronic Heart Failure - Case Presentation

SPOTLIGHT LECTURE: The Importance of Optimizing Heart Failure Therapies in the HF Patient Undergoing Structural Interventions

Case Presentation: Management of Advanced HF in a Patient with Severe Secondary MR

Use of Artificial Intelligence and Machine Learning to Improve Outcomes of Patients With HF

What Interventionalist/Structuralists Should Know About the US Guidelines for Medical Therapies for Heart Failure